Q-omics provides the consensus-scored UCN2 profile across patient tissues and cancer cell-line models. UCN2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UCN2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, UCN2 RNA expression shows 13,804 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BLCA, and TGCT as cancer lineages where UCN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UCN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UCN2 survival associations across molecular data types. UCN2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UCN2 RNA expression–survival associations across cancer types. High UCN2 expression shows unfavorable associations in KIRC, MESO, ACC, KIRP, LUAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UCN2 RNA expression.
This table summarizes UCN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UCN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UCN2 shows higher tumor expression in BLCA, HNSC, COAD, LUAD, STAD and LUSC. The BLCA box plot shows higher UCN2 RNA expression in tumor versus normal tissue (log2 FC = +2.852, t-test p < 0.001).
This table shows molecular features associated with UCN2 in patient tissues and cancer cell lines. In patient samples, UCN2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UCN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
